Please visit answersincme.com/ZWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer; Review the clinical profiles of TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer; and Apply guideline-concordant, evidence-based strategies to incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related